@prefix config: . @prefix meta: . @prefix rdf: . @prefix rdfs: . @prefix xsd: . @prefix owl: . @prefix dc: . @prefix dcmitype: . @prefix dcterms: . @prefix foaf: . @prefix geo: . @prefix om: . @prefix locn: . @prefix schema: . @prefix skos: . @prefix dbpedia: . @prefix p: . @prefix yago: . @prefix units: . @prefix geonames: . @prefix prv: . @prefix prvTypes: . @prefix doap: . @prefix void: . @prefix ir: . @prefix ou: . @prefix teach: . @prefix time: . @prefix datex: . @prefix aiiso: . @prefix vivo: . @prefix bibo: . @prefix fabio: . @prefix vcard: . @prefix swrcfe: . @prefix frapo: . @prefix org: . @prefix ei2a: . @prefix pto: . ou:bibtex "@article{Carrillo Norte1998,title = {Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors},journal = {Clinical Pharmacology and Therapeutics},year = {1998},volume = {64},number = {5},pages = {484-491},author = {Arlander, E. and Ekström, G. and Alm, C. and Carrillo, J.A. and Bielenstein, M. and Böttiger, Y. and Bertilsson, L. and Gustafsson, L.L.}}"; ou:vecesCitado "74"; dcterms:title "Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors"; bibo:issn "0009-9236"; dcterms:created "1998-01-01T00:00:00"^^xsd:dateTime; bibo:doi "10.1016/s0009-9236(98)90131-x"; vcard:url ; dcterms:contributor "Arlander, E.; Ekström, G.; Alm, C.; Carrillo, J.A.; Bielenstein, M.; Böttiger, Y.; Bertilsson, L.; Gustafsson, L.L."; ou:eid "2-s2.0-0031775019"; ou:urlScopus ; bibo:page_range "484-491"; fabio:hasPublicationYear "1998"; dcterms:creator "Arlander E."; ou:tipoPublicacion "Article"; a ou:Publicacion; vivo:identifier "1998-110"; bibo:volume "64"; dcterms:publisher "Clinical Pharmacology and Therapeutics"; ou:urlOrcid . ou:tienePublicacion .